BACKGROUND: Currently available vascular grafts for pediatric cardiovascular operations are limited by their inability to grow. Tissue-engineering techniques can be used to create vascular grafts with the potential for repair, remodeling, and growth. This study demonstrates the feasibility of constructing an autologous tissue-engineered venous conduit from bone marrow-derived vascular cells (BMVCs) in the ovine animal model. METHODS: Ovine mononuclear cells were isolated from the bone marrow, cultured in endothelial growth medium, and characterized with immunocytochemistry. Biodegradable tubular scaffolds were constructed from polyglycolic acid mesh coated with a copolymer of poly[epsilon-caprolactone-L-lactide]. Scaffolds were seeded at various cell concentrations and incubation times to optimize seeding conditions for the construction of an autologous venous conduit. Using optimized conditions, 6 tissue-engineered vascular grafts were implanted as inferior vena cava interposition grafts in juvenile lambs. Grafts were assessed for patency at days 1 to 30 postoperatively and explanted for histological and immunohistochemical analysis. RESULTS: A mixed cell population of BMVCs consisting of smooth muscle cells and endothelial cells was cultured from ovine sternal bone marrow. A seeding concentration of 2 x 10(6) cells/cm2 and 7 days of postseeding incubation were optimal for creating a confluent cellular layer on the polyglycolic acid/poly[epsilon-caprolactone-L-lactide]) scaffold. Grafts were explanted up to 4 weeks postoperatively. All grafts were patent without evidence of thrombosis. Histological evaluation of the explanted grafts demonstrated neo-endothelialization. Graft wall was composed of neo-tissue made up of residual polymer matrix, mesenchymal cells, and extracellular matrix without evidence of calcification. CONCLUSIONS: Bone marrow-derived vascular cells, containing endothelial and smooth muscle cells, can be isolated and cultured from ovine sternal bone marrow and used as a cell source for vascular tissue engineering. Our optimized techniques for BMVC harvest and seeding onto biodegradable scaffolds can be used for studying autologous tissue-engineered vascular grafts in the ovine animal model.
BACKGROUND: Currently available vascular grafts for pediatric cardiovascular operations are limited by their inability to grow. Tissue-engineering techniques can be used to create vascular grafts with the potential for repair, remodeling, and growth. This study demonstrates the feasibility of constructing an autologous tissue-engineered venous conduit from bone marrow-derived vascular cells (BMVCs) in the ovine animal model. METHODS: Ovine mononuclear cells were isolated from the bone marrow, cultured in endothelial growth medium, and characterized with immunocytochemistry. Biodegradable tubular scaffolds were constructed from polyglycolic acid mesh coated with a copolymer of poly[epsilon-caprolactone-L-lactide]. Scaffolds were seeded at various cell concentrations and incubation times to optimize seeding conditions for the construction of an autologous venous conduit. Using optimized conditions, 6 tissue-engineered vascular grafts were implanted as inferior vena cava interposition grafts in juvenile lambs. Grafts were assessed for patency at days 1 to 30 postoperatively and explanted for histological and immunohistochemical analysis. RESULTS: A mixed cell population of BMVCs consisting of smooth muscle cells and endothelial cells was cultured from ovine sternal bone marrow. A seeding concentration of 2 x 10(6) cells/cm2 and 7 days of postseeding incubation were optimal for creating a confluent cellular layer on the polyglycolic acid/poly[epsilon-caprolactone-L-lactide]) scaffold. Grafts were explanted up to 4 weeks postoperatively. All grafts were patent without evidence of thrombosis. Histological evaluation of the explanted grafts demonstrated neo-endothelialization. Graft wall was composed of neo-tissue made up of residual polymer matrix, mesenchymal cells, and extracellular matrix without evidence of calcification. CONCLUSIONS: Bone marrow-derived vascular cells, containing endothelial and smooth muscle cells, can be isolated and cultured from ovine sternal bone marrow and used as a cell source for vascular tissue engineering. Our optimized techniques for BMVC harvest and seeding onto biodegradable scaffolds can be used for studying autologous tissue-engineered vascular grafts in the ovine animal model.
Authors: Gustavo A Villalona; Brooks Udelsman; Daniel R Duncan; Edward McGillicuddy; Rajendra F Sawh-Martinez; Narutoshi Hibino; Christopher Painter; Tamar Mirensky; Benjamin Erickson; Toshiharu Shinoka; Christopher K Breuer Journal: Tissue Eng Part B Rev Date: 2010-06 Impact factor: 6.389
Authors: Jeffrey T Krawiec; Justin S Weinbaum; Claudette M St Croix; Julie A Phillippi; Simon C Watkins; J Peter Rubin; David A Vorp Journal: Tissue Eng Part A Date: 2014-09-16 Impact factor: 3.845
Authors: Richard P Visconti; Vladimir Kasyanov; Carmine Gentile; Jing Zhang; Roger R Markwald; Vladimir Mironov Journal: Expert Opin Biol Ther Date: 2010-03 Impact factor: 4.388
Authors: Jason D Roh; Gregory N Nelson; Matthew P Brennan; Tamar L Mirensky; Tai Yi; Tyrone F Hazlett; George Tellides; Albert J Sinusas; Jordan S Pober; W M Saltzman; Themis R Kyriakides; Christopher K Breuer Journal: Biomaterials Date: 2007-12-27 Impact factor: 12.479
Authors: Matthew P Brennan; Alan Dardik; Narutoshi Hibino; Jason D Roh; Gregory N Nelson; Xenophon Papademitris; Toshiharu Shinoka; Christopher K Breuer Journal: Ann Surg Date: 2008-09 Impact factor: 12.969
Authors: Benjamin Levi; Jason P Glotzbach; Victor W Wong; Emily R Nelson; Jeong Hyun; Derrick C Wan; Geoffrey C Gurtner; Michael T Longaker Journal: J Craniofac Surg Date: 2012-01 Impact factor: 1.046
Authors: Paula Fratini; Nathia Nathaly Rigoglio; Gustavo de Sá Schiavo Matias; Ana Claudia O Carreira; Rose Eli Grassi Rici; Maria Angelica Miglino Journal: Biores Open Access Date: 2018-07-01